---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-24-000004"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:20:44.804514+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q4 net revenue $178.1M, GAAP EPS $0.68; FY revenue $644.4M

## Summary
- Q4 2023 net revenue $178.1M (+32% YoY); GAAP net income $36.2M ($0.68 EPS).
- Adjusted non-GAAP Q4 net income $46.9M ($0.88 EPS) vs $37.6M ($0.73 EPS) in Q4 2022.
- Full-year net revenue $644.4M (+29% YoY); GAAP net income $137.5M ($2.60 EPS).
- Full-year adjusted non-GAAP net income $175.7M ($3.32 EPS) vs $103.2M ($1.97 EPS) in FY2022.
- CEO cited strong performance of glucagon, Primatene MIST, BAQSIMI acquisition, and BLA submission for Insulin Aspart.

## SEC filing metadata
- accession: 0001297184-24-000004
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718424000004/0001297184-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718424000004/amph-20240228x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-24-000004
- JSON: https://secwatch.observer/filing/0001297184-24-000004.json
- Plain text: https://secwatch.observer/filing/0001297184-24-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.